Prime medicine presents in vivo proof-of-concept data highlighting interim preclinical advances in its wilson's disease program and the broad potential of its universal liver-targeted lnp at esgct 31st annual congress

Delivery of prime editors with a proprietary, universal liver-targeted lnp was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies
PRME Ratings Summary
PRME Quant Ranking